Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials
about
Hepatitis C virus protease inhibitor-resistance mutations: our experience and reviewMechanisms of Hepatitis C Viral Resistance to Direct Acting AntiviralsMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceHCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, BrazilModeling viral evolutionary dynamics after telaprevir-based treatmentGeno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral AgentsGlobal prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome dataVirologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevirPrevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region.Telaprevir-based treatment effects on hepatitis C virus in liver and blood.A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort.Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions.Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.Hepatitis C virus drug resistance-associated substitutions: State of the art summary.The role of HCV proteins on treatment outcomes.NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing SimeprevirMolecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage.Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study.Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samplesHepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse
P2860
Q24628717-6600E0D8-C88A-468E-9655-9F50161B9874Q26773321-A5AEAAFF-B979-4F44-8E79-A502FCBB2A5BQ27469038-E89A350E-A178-4EFB-B9B7-B924257226AFQ28538943-05ED8684-EB2F-4405-AF09-5A5253F03B4CQ28542375-417839F3-8DA1-44C9-BFD2-5B4348D4A18DQ28552269-B9585B1A-DDB7-4C29-88F0-AE9DC11CDBF3Q31042796-A8DD336F-CEE8-4059-8F46-CC6EAF62DE95Q33648185-EA6AC70D-7333-4535-B903-2978FDF7B5EEQ34998753-82767C99-3B4A-4CF6-9E16-E15D2202BB16Q35129251-28EFB4BF-CA82-4E9B-9C96-20B1D06900AAQ35449696-8DA9C688-46E1-4000-81BA-879825DBF0F8Q35757761-1F6FC919-F35F-4FAB-98EB-4A78F23B8393Q36506480-3126AC3B-E2CB-40D3-A12A-635D5CB2C115Q36933403-6D7E5805-A2E6-4F52-9329-9A41029AB7E4Q36988456-CBD9D24A-571D-4179-9A99-75570E61714CQ38095820-66D0A5CD-A9F6-418C-B466-DC47115B60FFQ38193551-31855681-6481-49D1-ADED-1140E948F3E7Q38533619-3BD4656E-A4A3-4D47-9235-78B80D073FB9Q38668968-CA5601D2-0709-4C4D-B0B5-34D6DE5A6FB8Q38699377-C215F4F3-A0C5-44A6-8945-72725EB17267Q38972180-242BE01F-F12C-4499-872A-6B32E4222A3FQ39084966-DC7793F2-0F87-4777-B792-231C6C75C7D1Q39121699-A8D24C68-22E2-4539-BF32-D781CD1DB412Q40518926-2A463A04-CEC3-4342-A9C2-CBC5D3A65AB3Q40867184-B46DD493-4B09-48C4-887E-A0B30EB8C2F8Q40944812-F9FABA12-01EF-4780-B203-03027EE695AAQ40988716-C0A8FA6F-AC89-45DC-82E5-1CB22CB90B80Q41127462-CEB65D61-86D3-456E-AF25-695931510118Q41259954-9529389F-FFB1-4B68-B028-506911882CC2Q41360324-9D185BD7-134D-4A38-8CE6-028A57406AD7Q41658636-826FD2F6-3079-4C34-915F-8CAF3A22A482Q42000392-B94E7CC6-36E1-4B98-8754-A91A7E7FC539Q42286521-3FEE71AA-5ADA-45CE-9E1D-492AF4D1DF7CQ42982310-CAF6E5DB-63C9-451B-8448-C097B0244D2EQ44519022-6820CF18-B144-477F-9ACC-A3FE91A89B53Q58795595-C270DD1E-F01A-44BD-8109-797B7885A4AB
P2860
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials
description
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2012
@ast
im Januar 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2012)
@en
vedecký článok (publikovaný 2012)
@sk
vědecký článek publikovaný v roce 2012
@cs
wetenschappelijk artikel (gepubliceerd in 2012)
@nl
наукова стаття, опублікована у 2012
@uk
مقالة علمية (نشرت عام 2012)
@ar
name
Hepatitis C viral evolution in ...... sed therapy in clinical trials
@ast
Hepatitis C viral evolution in ...... sed therapy in clinical trials
@en
Hepatitis C viral evolution in ...... sed therapy in clinical trials
@nl
type
label
Hepatitis C viral evolution in ...... sed therapy in clinical trials
@ast
Hepatitis C viral evolution in ...... sed therapy in clinical trials
@en
Hepatitis C viral evolution in ...... sed therapy in clinical trials
@nl
prefLabel
Hepatitis C viral evolution in ...... sed therapy in clinical trials
@ast
Hepatitis C viral evolution in ...... sed therapy in clinical trials
@en
Hepatitis C viral evolution in ...... sed therapy in clinical trials
@nl
P2093
P2860
P3181
P1433
P1476
Hepatitis C viral evolution in ...... sed therapy in clinical trials
@en
P2093
Ann D Kwong
Ann Tigges
Bambang Adiwijaya
Doug J Bartels
Eileen Z Zhang
Gaston Picchio
Inge Dierynck
Ira M Jacobson
James C Sullivan
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0034372
P407
P577
2012-01-01T00:00:00Z